Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) – a register-based study
IVIg treatment represents an important marker for high direct medical costs among patients with MG. The costs continue to be high during the first five years after MG diagnosis.
Authors
- Ingrid Engebretsen (ORCID: https://orcid.org/0000-0001-9608-6731)
- Ivar Sønbø Kristiansen (ORCID: https://orcid.org/0000-0002-5389-6010)
- Nils Erik Gilhus (ORCID: https://orcid.org/0000-0001-6522-5102)
- Ingrid Lindberg (ORCID: https://orcid.org/0000-0002-6549-6065)
- Christoffer Bugge (ORCID: https://orcid.org/0000-0002-0766-2870)
- Fredrik Arneberg
- Erik Magnus Sæther
Institutions
- Statistics Norway (NO)
- University of Southern Denmark (DK)
- University of Oslo (NO)
- Haukeland University Hospital (NO)
- 657 Oslo (NO)
- University of Bergen (NO)
Publication Details
- Journal
- Journal of Neurology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1007/s00415-024-12768-5
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.37